BR112012033227A2 - análogos do glucagon - Google Patents
análogos do glucagonInfo
- Publication number
- BR112012033227A2 BR112012033227A2 BR112012033227A BR112012033227A BR112012033227A2 BR 112012033227 A2 BR112012033227 A2 BR 112012033227A2 BR 112012033227 A BR112012033227 A BR 112012033227A BR 112012033227 A BR112012033227 A BR 112012033227A BR 112012033227 A2 BR112012033227 A2 BR 112012033227A2
- Authority
- BR
- Brazil
- Prior art keywords
- glucagon
- methods
- glucagon analogs
- peptides
- analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
análogos do glucagon. a invenção fornece materiais e métodos para promover a perda de peso ou impedir o ganho de peso sem afetar o controle glicêmico. em particular, a invenção fornece novos peptídeos análogos de glucagon eficazes em tais métodos. os peptídeos podem mediar o seu efeito por ter seletividade aumentada para o receptor de glp-1 em comparação com glucagon humano.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201000550 | 2010-06-23 | ||
US35862310P | 2010-06-25 | 2010-06-25 | |
PCT/DK2011/000067 WO2011160630A2 (en) | 2010-06-23 | 2011-06-23 | Glucagon analogues |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012033227A2 true BR112012033227A2 (pt) | 2017-06-20 |
Family
ID=44630045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012033227A BR112012033227A2 (pt) | 2010-06-23 | 2011-06-23 | análogos do glucagon |
Country Status (22)
Country | Link |
---|---|
US (2) | US9403894B2 (pt) |
EP (1) | EP2585481B1 (pt) |
JP (1) | JP5937582B2 (pt) |
KR (1) | KR20130086339A (pt) |
CN (1) | CN103038250A (pt) |
AP (1) | AP3286A (pt) |
AR (1) | AR081975A1 (pt) |
AU (1) | AU2011269427A1 (pt) |
BR (1) | BR112012033227A2 (pt) |
CA (1) | CA2802889A1 (pt) |
CL (1) | CL2012003643A1 (pt) |
CO (1) | CO6660484A2 (pt) |
EA (1) | EA201291233A1 (pt) |
EC (1) | ECSP12012351A (pt) |
MX (1) | MX2012014774A (pt) |
NZ (1) | NZ604033A (pt) |
PE (1) | PE20130326A1 (pt) |
SG (1) | SG186276A1 (pt) |
TN (1) | TN2012000567A1 (pt) |
TW (1) | TW201202265A (pt) |
UY (1) | UY33462A (pt) |
WO (1) | WO2011160630A2 (pt) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1877435E (pt) | 2005-05-04 | 2011-05-24 | Zealand Pharma As | An?logos de p?ptido-2 semelhante a glucagon |
NZ597554A (en) | 2006-11-08 | 2014-04-30 | Zealand Pharma As | Selective glucagon-like-peptide-2 (glp-2) analogues |
US8685919B2 (en) | 2008-12-15 | 2014-04-01 | Zealand Pharma A/S | Glucagon analogues |
DK2370460T3 (da) | 2008-12-15 | 2014-08-04 | Zealand Pharma As | Glucagon analoger |
KR20110126591A (ko) | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
MX2011006315A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
HUE026255T2 (en) | 2009-07-13 | 2016-06-28 | Zealand Pharma As | Acylated glucagon analogues |
AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
CN103068841A (zh) | 2010-06-24 | 2013-04-24 | 西兰制药公司 | 胰高血糖素类似物 |
WO2012098462A1 (en) * | 2011-01-20 | 2012-07-26 | Zealand Pharma A/S | Combination of acylated glucagon analogues with insulin analogues |
MY167234A (en) | 2011-09-23 | 2018-08-14 | Novo Nordisk As | Novel glucagon analogues |
WO2013092703A2 (en) * | 2011-12-23 | 2013-06-27 | Zealand Pharma A/S | Glucagon analogues |
TR201815338T4 (tr) | 2012-05-03 | 2018-11-21 | Zealand Pharma As | Gıp-glp-1 dual agonist bileşikleri ve yöntemler. |
TR201802689T4 (tr) * | 2012-05-03 | 2018-03-21 | Zealand Pharma As | Glukagon benzeri peptit-2 (glp-2) analogları. |
WO2013186240A2 (en) | 2012-06-14 | 2013-12-19 | Sanofi | Exendin-4 peptide analogues |
ES2620111T3 (es) | 2012-07-23 | 2017-06-27 | Zealand Pharma A/S | Análogos de glucagón |
GB2505941A (en) * | 2012-09-17 | 2014-03-19 | Imp Innovations Ltd | Peptide analogues of glucagon for the treatment of obesity and diabetes |
WO2014041375A1 (en) | 2012-09-17 | 2014-03-20 | Imperial Innovations Limited | Peptide analogues of glucagon and glp1 |
TWI608013B (zh) * | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
HUE038748T2 (hu) | 2012-12-21 | 2018-11-28 | Sanofi Sa | Exendin-4 származékok, mint duális GLP1/GIP- vagy trigonális GLP1/GIP/glukagon-agonisták |
WO2014147124A1 (en) | 2013-03-21 | 2014-09-25 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
DK2976325T3 (en) | 2013-03-21 | 2017-06-06 | Sanofi Aventis Deutschland | SYNTHESIS OF PEPTIDE PRODUCTS CONTAINING CYCLIC IMID |
WO2014161835A1 (en) | 2013-04-03 | 2014-10-09 | Sanofi | Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof |
RS59124B1 (sr) | 2013-04-18 | 2019-09-30 | Novo Nordisk As | Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
TWI666220B (zh) | 2013-10-17 | 2019-07-21 | 丹麥商西蘭製藥公司 | 醯化升糖素類似物 |
KR102310389B1 (ko) | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | Gip-glp-1 이원 효능제 화합물 및 방법 |
MX369770B (es) | 2013-11-06 | 2019-11-21 | Zealand Pharma As | Compuestos agonistas triples de glucagón-glp-1-gip. |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
TW201609800A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 做為雙重glp-1/升糖素受體促效劑之艾塞那肽-4胜肽類似物 |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー/エス | 医療用のglp−1/グルカゴン受容体コアゴニスト |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
EP3212218B1 (en) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Gip agonist compounds and methods |
TN2017000349A1 (en) | 2015-02-17 | 2019-01-16 | Lilly Co Eli | Nasal powder formulation for treatment of hypoglycemia |
CN107567459B (zh) | 2015-03-18 | 2021-09-24 | 西兰制药公司 | 胰淀素类似物 |
WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
CN107636010B (zh) | 2015-04-16 | 2021-10-01 | 西兰制药公司 | 酰化胰高血糖素类似物 |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
WO2017214543A1 (en) | 2016-06-09 | 2017-12-14 | Amidebio, Llc | Glucagon analogs and methods of use thereof |
RS61937B1 (sr) | 2016-08-05 | 2021-07-30 | Boehringer Ingelheim Int | Oksadiazolopiridin derivati za primenu kao inhibitori grelin o-acil transferaze (goat) |
AR109514A1 (es) | 2016-09-09 | 2018-12-19 | Zealand Pharma As | Análogos de amilina |
KR101887577B1 (ko) * | 2016-10-19 | 2018-09-10 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
AR110299A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
BR112019010624A2 (pt) | 2016-12-09 | 2019-10-22 | Zealand Pharma As | agonistas duplos de glp-1/glp-2 acilados e composição |
JP7211659B2 (ja) * | 2017-08-16 | 2023-01-24 | ドン-ア エスティ カンパニー リミテッド | アシル化オキシントモジュリンペプチド類似体 |
SG11202006302TA (en) | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
WO2019149658A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
PE20210175A1 (es) | 2018-02-02 | 2021-01-29 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat) |
JOP20200190A1 (ar) | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | مشتقات أوكسادايازولو بيريدين بها استبدال ببنزيل -، (بيريدين -3- يل) ميثيل - أو (بيريدين -4- يل) ميثيل كمثبطات جريلين o- أسيل ترانسفيراز (goat) |
BR112020020652A2 (pt) * | 2018-04-10 | 2021-03-02 | Sanofi-Aventis Deutschland Gmbh | método para clivagem de peptídeos ligados à fase sólida a partir da fase sólida |
EP3774838B1 (en) | 2018-04-10 | 2022-08-10 | Sanofi-Aventis Deutschland GmbH | Lixisenatide synthesis with capping |
EP3901173A4 (en) | 2018-12-21 | 2022-11-23 | Jiangsu Hengrui Medicine Co., Ltd. | BISPECIFIC PROTEIN |
TWI771669B (zh) | 2019-04-26 | 2022-07-21 | 美商美國禮來大藥廠 | 製備穩定胜肽調配物之方法 |
CR20220206A (es) | 2019-11-11 | 2022-06-16 | Boehringer Ingelheim Int | Agonistas del receptor npy2 |
CN115884974A (zh) | 2020-05-22 | 2023-03-31 | 勃林格殷格翰国际有限公司 | 制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的方法 |
CN113278060B (zh) * | 2020-05-29 | 2022-03-25 | 东莞云璟生物技术有限公司 | Glp-1/胰高血糖素双重激动剂融合蛋白 |
CN116171282A (zh) | 2020-08-07 | 2023-05-26 | 勃林格殷格翰国际有限公司 | 可溶npy2受体激动剂 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ202757A (en) | 1981-12-23 | 1985-11-08 | Novo Industri As | Peptides and medicaments |
CZ300837B6 (cs) | 1996-08-30 | 2009-08-26 | Novo Nordisk A/S | Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití |
JP2001505872A (ja) | 1996-09-09 | 2001-05-08 | ジーランド ファーマシューティカルズ アクティーゼルスカブ | α―ヒドロキシ酸リンカーを含むペプチドプロドラッグ |
ATE290014T1 (de) | 1996-09-09 | 2005-03-15 | Zealand Pharma As | Festphasen-peptidsynthese |
BR9815670A (pt) | 1997-11-14 | 2000-10-17 | Amylin Pharmaceuticals Inc | Compostos agonistas de exendina |
CA2321026A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
JP3702181B2 (ja) | 1998-12-07 | 2005-10-05 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Glp−1の類似体 |
US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
PL351326A1 (en) | 1999-03-17 | 2003-04-07 | Novo Nordisk As | Method for acylating peptides and novel acylating agents |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
AU2002346491A1 (en) | 2001-12-19 | 2003-07-09 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
PL374949A1 (en) | 2001-12-20 | 2005-11-14 | Eli Lilly And Company | Insulin molecule having protracted time action |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
US20060217290A1 (en) | 2003-04-29 | 2006-09-28 | Kohn Wayne D | Insulin analogs having protracted time action |
DK1891105T3 (da) | 2005-06-13 | 2012-07-16 | Imp Innovations Ltd | Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd |
US20090202497A1 (en) | 2005-08-23 | 2009-08-13 | The General Hospital Corporation | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
ES2507098T3 (es) | 2005-11-07 | 2014-10-14 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
US8343914B2 (en) | 2006-01-06 | 2013-01-01 | Case Western Reserve University | Fibrillation resistant proteins |
EP1991574B1 (en) | 2006-02-22 | 2016-10-12 | Merck Sharp & Dohme Corp. | Oxyntomodulin derivatives |
ZA200900545B (en) | 2006-07-18 | 2010-03-31 | Sanofi Aventis | Antagonist antibody against EPHA2 for the treatment of cancer |
WO2008043033A2 (en) | 2006-10-04 | 2008-04-10 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
US7994122B2 (en) | 2007-06-15 | 2011-08-09 | Zealand Pharma A/S | Glucagon analogues |
EP2025684A1 (en) | 2007-08-15 | 2009-02-18 | Zealand Pharma A/S | Glucagon analogues |
US8946148B2 (en) | 2007-11-20 | 2015-02-03 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
HUE030537T2 (en) | 2008-01-09 | 2017-05-29 | Sanofi Aventis Deutschland | New insulin analogues with a particularly prolonged effect profile |
AU2009203810B2 (en) | 2008-01-09 | 2013-07-25 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
US8993516B2 (en) | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
RU2010147076A (ru) | 2008-04-22 | 2012-05-27 | Кейз Вестерн Ризев Юнивесити (Us) | Аналоги инсулина специфичные к изоформам |
TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
MX2010012695A (es) | 2008-06-17 | 2011-03-15 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico. |
EP2300037B1 (en) | 2008-06-17 | 2016-03-30 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
RU2555557C2 (ru) | 2008-07-31 | 2015-07-10 | Кейз Вестерн Ризев Юнивесити | Инсулин, стабилизированный галогеном |
DK2370460T3 (da) | 2008-12-15 | 2014-08-04 | Zealand Pharma As | Glucagon analoger |
US8685919B2 (en) | 2008-12-15 | 2014-04-01 | Zealand Pharma A/S | Glucagon analogues |
KR20110126591A (ko) | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
MX2011006315A (es) * | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
AU2009335715B2 (en) | 2008-12-19 | 2016-09-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
CN102256992B (zh) | 2008-12-19 | 2015-04-22 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物 |
CN101519446A (zh) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | 一种重组人胰岛素及其类似物的制备方法 |
HUE026255T2 (en) | 2009-07-13 | 2016-06-28 | Zealand Pharma As | Acylated glucagon analogues |
KR20120128129A (ko) * | 2010-01-20 | 2012-11-26 | 질랜드 파마 에이/에스 | 심장 병태의 치료 |
AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
CN103068841A (zh) | 2010-06-24 | 2013-04-24 | 西兰制药公司 | 胰高血糖素类似物 |
WO2012098462A1 (en) | 2011-01-20 | 2012-07-26 | Zealand Pharma A/S | Combination of acylated glucagon analogues with insulin analogues |
WO2013092703A2 (en) | 2011-12-23 | 2013-06-27 | Zealand Pharma A/S | Glucagon analogues |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
TWI666220B (zh) | 2013-10-17 | 2019-07-21 | 丹麥商西蘭製藥公司 | 醯化升糖素類似物 |
-
2011
- 2011-06-22 AR ARP110102166A patent/AR081975A1/es unknown
- 2011-06-22 UY UY0001033462A patent/UY33462A/es not_active Application Discontinuation
- 2011-06-23 TW TW100122081A patent/TW201202265A/zh unknown
- 2011-06-23 KR KR1020137000529A patent/KR20130086339A/ko not_active Application Discontinuation
- 2011-06-23 MX MX2012014774A patent/MX2012014774A/es not_active Application Discontinuation
- 2011-06-23 CA CA2802889A patent/CA2802889A1/en not_active Abandoned
- 2011-06-23 EA EA201291233A patent/EA201291233A1/ru unknown
- 2011-06-23 PE PE2012002434A patent/PE20130326A1/es not_active Application Discontinuation
- 2011-06-23 AP AP2013006669A patent/AP3286A/xx active
- 2011-06-23 JP JP2013515697A patent/JP5937582B2/ja not_active Expired - Fee Related
- 2011-06-23 CN CN2011800305150A patent/CN103038250A/zh active Pending
- 2011-06-23 EP EP11741513.3A patent/EP2585481B1/en active Active
- 2011-06-23 NZ NZ604033A patent/NZ604033A/en not_active IP Right Cessation
- 2011-06-23 BR BR112012033227A patent/BR112012033227A2/pt not_active IP Right Cessation
- 2011-06-23 WO PCT/DK2011/000067 patent/WO2011160630A2/en active Application Filing
- 2011-06-23 US US13/702,841 patent/US9403894B2/en not_active Expired - Fee Related
- 2011-06-23 SG SG2012090890A patent/SG186276A1/en unknown
- 2011-06-23 AU AU2011269427A patent/AU2011269427A1/en not_active Abandoned
-
2012
- 2012-11-30 TN TNP2012000567A patent/TN2012000567A1/en unknown
- 2012-12-20 EC ECSP12012351 patent/ECSP12012351A/es unknown
- 2012-12-21 CO CO12232550A patent/CO6660484A2/es unknown
- 2012-12-21 CL CL2012003643A patent/CL2012003643A1/es unknown
-
2016
- 2016-06-27 US US15/194,025 patent/US20160304576A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9403894B2 (en) | 2016-08-02 |
UY33462A (es) | 2012-01-31 |
CA2802889A1 (en) | 2011-12-29 |
NZ604033A (en) | 2014-12-24 |
CO6660484A2 (es) | 2013-04-30 |
JP5937582B2 (ja) | 2016-06-22 |
ECSP12012351A (es) | 2013-01-31 |
WO2011160630A2 (en) | 2011-12-29 |
EP2585481A2 (en) | 2013-05-01 |
AU2011269427A1 (en) | 2012-12-20 |
US20130157935A1 (en) | 2013-06-20 |
CN103038250A (zh) | 2013-04-10 |
SG186276A1 (en) | 2013-01-30 |
EP2585481B1 (en) | 2015-08-19 |
KR20130086339A (ko) | 2013-08-01 |
PE20130326A1 (es) | 2013-03-17 |
CL2012003643A1 (es) | 2013-08-02 |
TW201202265A (en) | 2012-01-16 |
AP3286A (en) | 2015-05-31 |
US20160304576A1 (en) | 2016-10-20 |
AP2013006669A0 (en) | 2013-01-31 |
AR081975A1 (es) | 2012-10-31 |
WO2011160630A3 (en) | 2012-02-16 |
JP2013534919A (ja) | 2013-09-09 |
EA201291233A1 (ru) | 2013-07-30 |
TN2012000567A1 (en) | 2014-04-01 |
MX2012014774A (es) | 2013-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012033227A2 (pt) | análogos do glucagon | |
BR112012033225A2 (pt) | análogos do glucagon | |
PH12014501336A1 (en) | Glucagon analogues | |
CY1122539T1 (el) | Αναλογα γλυκαγονης | |
ECSP12011593A (es) | Análogos de glucagón acilados | |
TN2011000295A1 (en) | Glucagon analogues | |
MX2011006314A (es) | Analogos de glucagon. | |
PH12015500531A1 (en) | Glucagon analogues | |
PH12016500675B1 (en) | Acylated glucagon analogues | |
DK2158214T3 (da) | Glukagonanaloger | |
BR112017022009A2 (pt) | ?composto, método de produção e síntese do mesmo e seu uso, composição e conjunto terapêutico? | |
NZ593813A (en) | Glucagon analogues | |
MX352205B (es) | Sistemas de expresion. | |
UY31717A1 (es) | (pirazolilcarbonil) imidazolidinonas sustituidas y su uso | |
BR112016009962A2 (pt) | superagonistas de ação prolongada de hormônio glicoproteico | |
ECSP15009978A (es) | Análogos de glucagón | |
CO6382136A2 (es) | Análogos de glucagón | |
TN2011000667A1 (en) | Acylated glucagon analogues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |